Возможности мультипараметрической магнитно-резонансной томографии при проведении фьюжн-биопсии под её контролем в диагностике рака предстательной железы: текущий статус
- Авторы: Testini V.1,2, Eusebi L.3, Guerra F.S.1, Giannubilo W.4, Di Biase M.5, Russo A.2, Guglielmi G.1,2,6
-
Учреждения:
- Университет Фоджи
- Monsignor Raffaele Dimiccoli Hospital
- Carlo Urbani Hospital
- Ospedale Civile
- Santa Maria della Misericordia Hospital
- Casa Sollievo della Sofferenza Hospital
- Выпуск: Том 5, № 2 (2024)
- Страницы: 283-302
- Раздел: Обзоры
- URL: https://journals.rcsi.science/DD/article/view/264839
- DOI: https://doi.org/10.17816/DD623183
- ID: 264839
Цитировать
Полный текст
Аннотация
В данном обзоре освещается роль мультипараметрической магнитно-резонансной томографии в выявлении рака предстательной железы, в частности — при биопсии простаты. Использование мультипараметрической магнитно-резонансной томографии в диагностике рака простаты позволяет также применять её для биопсии. Мультипараметрическая магнитно-резонансная томография, по данным многих исследований, обладает высокой чувствительностью и специфичностью в ранней диагностике и стадировании у пациентов с сохраняющимся высоким уровнем простатспецифического антигена, несмотря на предыдущие отрицательные биопсии простаты, а также при ведении пациентов, находящихся под активным наблюдением.
Для проведения прицельной биопсии простаты существует три типа наведения: когнитивная фьюжн-биопсия; прямая биопсия, направляемая магнитно-резонансной томографией и выполняемая внутри томографа (in-bore); программная корегистрация снимков предоперационной магнитно-резонансной томографии с интраоперационным ультразвуковым исследованием с помощью фьюжн-устройства. При этом при проведении прицельной биопсии результаты мультипараметрической магнитно-резонансной томографии накладываются в цифровом виде на изображения трансректального ультразвукового исследования в реальном времени.
Каждый метод имеет свои преимущества и недостатки. Прицельная биопсия с помощью магнитно-резонансной томографии улучшает качество гистологических результатов по сравнению с другими подходами, выявляя значимые индексные поражения с точностью до 90%. Правильное стадирование позволяет выбрать оптимальные варианты лечения, адекватно оценить прогноз, снизить частоту новых биопсий и осложнений. В настоящее время главная задача состоит в том, чтобы сделать биопсию в сочетании с магнитно-резонансной томографией более доступной и стандартизировать технику проведения процедуры, что позволит минимизировать межоператорскую вариабельность в зависимости от используемой системы.
Полный текст
Открыть статью на сайте журналаОб авторах
Valentina Testini
Университет Фоджи; Monsignor Raffaele Dimiccoli Hospital
Email: testinivalentina@gmail.com
ORCID iD: 0000-0003-1231-5213
MD
Италия, Фоджа; БарлеттаLaura Eusebi
Carlo Urbani Hospital
Email: lauraeu@virgilio.it
ORCID iD: 0000-0002-4172-5126
MD
Италия, ЕзиFrancesco Saverio Guerra
Университет Фоджи
Email: francesco.rino@gmail.com
ORCID iD: 0000-0003-3923-3429
MD
Италия, ФоджаWilly Giannubilo
Ospedale Civile
Email: willygiannubilo@virgilio.it
MD
Италия, Чивитанова-МаркеManuel Di Biase
Santa Maria della Misericordia Hospital
Email: manuel.dibiase@ospedale.perugia.it
MD
Италия, ПеруджаAnnunziata Russo
Monsignor Raffaele Dimiccoli Hospital
Email: tittyrusso-23@libero.it
MD
Италия, БарлеттаGiuseppe Guglielmi
Университет Фоджи; Monsignor Raffaele Dimiccoli Hospital; Casa Sollievo della Sofferenza Hospital
Автор, ответственный за переписку.
Email: giuseppe.guglielmi@unifg.it
ORCID iD: 0000-0002-4325-8330
MD, Professor
Италия, Фоджа; Барлетта; ФоджаСписок литературы
- Mottet N., Bellmunt J., Bolla M., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent // Eur Urol. 2017. Vol. 71, N 4. P. 618–629. doi: 10.1016/j.eururo.2016.08.003
- Siddiqui M.M., Rais-Bahrami S., Truong H., et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy // Eur Urol. 2013. Vol. 64, N 5. P. 713–719. doi: 10.1016/j.eururo.2013.05.059
- Bjurlin M.A., Meng X., Le Nobin J., et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment // J Urol. 2014. Vol. 192, N 3. P. 648–658. doi: 10.1016/j.juro.2014.03.117
- [WITHDRAWN] Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing (guidance) [Internet]. UK : Public Health England, 2016. Доступ по ссылке: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks
- Hamoen E.H.J., de Rooij M., Witjes J.A., Barentsz J.O., Rovers M.M. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis // Eur Urol. 2015. Vol. 67, N 6. P. 1112–1121. doi: 10.1016/j.eururo.2014.10.033
- Ventrella E., Eusebi L., Carpagnano F.A., et al. Multiparametric MRI of Prostate Cancer: Recent Advances // Curr Radiol Rep. 2020. Vol. 8. doi: 10.1007/s40134-020-00363-1
- Portalez D., Mozer P., Cornud F., et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients // Eur Urol. 2012. Vol. 62, N 6. P. 986–996. doi: 10.1016/j.eururo.2012.06.044
- Kuru T.H., Roethke M.C., Rieker P., et al. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate // BJU Int. 2013. Vol. 112, N 8. P. 1080–1087. doi: 10.1111/bju.12259
- Carpagnano F., Eusebi L., Tupputi U., et al. Multiparametric MRI: Local Staging of Prostate Cancer. Current Radiology Reports. 2020. Vol. 8. doi: 10.1007/s40134-020-00374-y
- Arsov C., Rabenalt R., Blondin D., et al. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies // Eur Urol. 2015. Vol. 68, N 4. P. 713–720. doi: 10.1016/j.eururo.2015.06.008
- Hambrock T., Somford D.M., Hoeks C., et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen // J Urol. 2010. Vol. 183, N 2. P. 520–527. doi: 10.1016/j.juro.2009.10.022
- Tyson M.D., Arora S.S., Scarpato K.R., Barocas D. Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer // Urol Oncol. 2016. Vol. 34, N 7. P. 326–332. doi: 10.1016/j.urolonc.2016.03.005
- Wolters T., Montironi R., Mazzucchelli R., et al. Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy // Prostate. 2012. Vol. 72, N 1. P. 108–115. doi: 10.1002/pros.21415
- Moore C.M., Robertson N.L., Arsanious N., et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review // Eur Urol. 2013. Vol. 63, N 1. P. 125–140. doi: 10.1016/j.eururo.2012.06.004
- Puech P., Rouvière O., Renard-Penna R., et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy — prospective multicenter study // Radiology. 2013. Vol. 268, N 2. P. 461–469. doi: 10.1148/radiol.13121501
- Labanaris A.P., Engelhard K., Zugor V., Nützel R., Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate // Prostate Cancer Prostatic Dis. 2010. Vol. 13, N 1. P. 65–70. doi: 10.1038/pcan.2009.41
- Williams I.S., McVey A., Perera S., et al. Modern paradigms for prostate cancer detection and management // Med J Aust. 2022. Vol. 217, N 8. P. 424–433. doi: 10.5694/mja2.51722
- Haffner J., Lemaitre L., Puech P., et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection // BJU Int. 2011. Vol. 108, N 8 Pt 2. P. E171–E178. doi: 10.1111/j.1464-410X.2011.10112.x
- Labanaris A.P., Zugor V., Smiszek R., et al. Guided e-MRI prostate biopsy can solve the discordance between Gleason score biopsy and radical prostatectomy pathology // Magn Reson Imaging. 2010. Vol. 28, N 7. P. 943–946. doi: 10.1016/j.mri.2010.03.041
- Stephenson S.K., Chang E.K., Marks L.S. Screening and detection advances in magnetic resonance image-guided prostate biopsy // Urol Clin North Am. 2014. Vol. 41, N 2. P. 315–326. doi: 10.1016/j.ucl.2014.01.007
- Vourganti S., Rastinehad A., Yerram N., et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies // J Urol. 2012. Vol. 188, N 6. P. 2152–2157. doi: 10.1016/j.juro.2012.08.025
- Siddiqui M.M., Rais-Bahrami S., Turkbey B., et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer // JAMA. 2015. Vol. 313, N 4. P. 390–397. doi: 10.1001/jama.2014.17942
- Quentin M., Schimmöller L., Arsov C., et al. 3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions characterization // Acta Radiol. 2013. Vol. 54, N 10. P. 1224–1229. doi: 10.1177/0284185113492972
- Hoeks C.M., Schouten M.G., Bomers J.G., et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers // Eur Urol. 2012. Vol. 62, N 5. P. 902–909. doi: 10.1016/j.eururo.2012.01.047
- Marks L., Young S., Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy // Curr Opin Urol. 2013. Vol. 23, N 1. P. 43–50. doi: 10.1097/MOU.0b013e32835ad3ee
- Monni F., Fontanella P., Grasso A., et al. Magnetic resonance imaging in prostate cancer detection and management: a systematic review // Minerva Urol Nefrol. 2017. Vol. 69, N 6. P. 567–578. doi: 10.23736/S0393-2249.17.02819-3
- Schlaier J.R., Warnat J., Dorenbeck U., et al. Image fusion of MR images and real-time ultrasonography: evaluation of fusion accuracy combining two commercial instruments, a neuronavigation system and a ultrasound system // Acta Neurochir (Wien). 2004. Vol. 146, N 3. P. 271–276. doi: 10.1007/s00701-003-0155-6
- Pokorny M.R., de Rooij M., Duncan E., et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies // Eur Urol. 2014. Vol. 66, N 1. P. 22–29. doi: 10.1016/j.eururo.2014.03.002
- Kuru T.H., Roethke M.C., Seidenader J., et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer // J Urol. 2013. Vol. 190, N 4. P. 1380–1386. doi: 10.1016/j.juro.2013.04.043
- Serefoglu E.C., Altinova S., Ugras N.S., et al. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer? // Can Urol Assoc J. 2013. Vol. 7, N 5-6. P. E293–E298. doi: 10.5489/cuaj.11224
- Baco E., Ukimura O., Rud E., et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients // Eur Urol. 2015. Vol. 67, N 4. P. 787–794. doi: 10.1016/j.eururo.2014.08.077
- Cerantola Y., Dragomir A., Tanguay S., et al. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer // Urol Oncol. 2016. Vol. 34, N 3. P. 119.e1–119.e9. doi: 10.1016/j.urolonc.2015.09.010
- Delongchamps N.B., Peyromaure M., Schull A., et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies // J Urol. 2013. Vol. 189, N 2. P. 493–499. doi: 10.1016/j.juro.2012.08.195
- Bax J., Cool D., Gardi L., et al. Mechanically assisted 3D ultrasound guided prostate biopsy system // Med Phys. 2008. Vol. 35, N 12. P. 5397–5410. doi: 10.1118/1.3002415
- US Preventive Services Task Force; Grossman D.C., Curry S.J., et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement // JAMA. 2018. Vol. 319, N 18. P. 1901–1913. Erratum in: JAMA. 2018. Vol. 319, N 23. P. 2443. doi: 10.1001/jama.2018.3710
- Arnsrud Godtman R., Holmberg E., Lilja H., Stranne J., Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial // Eur Urol. 2015. Vol. 68, N 3. P. 354–360. doi: 10.1016/j.eururo.2014.12.006
- Engler J., Dahlhaus A., Güthlin C. The readiness of German GPs to recommend and conduct cancer screening is associated with patient-physician gender concordance. Results of a survey // Eur J Gen Pract. 2017. Vol. 23, N 1. P. 11–19. doi: 10.1080/13814788.2016.1240166
- Nordström T., Aly M., Clements M.S., et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011 // Eur Urol. 2013. Vol. 63, N 3. P. 419–425. doi: 10.1016/j.eururo.2012.10.001
- Van Poppel H., Roobol M.J., Chapple C.R., et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021 // Eur Urol. 2021. Vol. 80, N 6. P. 703–711. doi: 10.1016/j.eururo.2021.07.024
- Mottet N., van den Bergh R.C.N., Briers E., et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent // Eur Urol. 2021. Vol. 79, N 2. P. 243–262. doi: 10.1016/j.eururo.2020.09.042
- Collen S., Van Poppel H. Early detection and diagnosis of prostate cancer in well informed men: the way forward for Europe // Belg J Med Oncol. 2020. Vol. 14. P. 321–326.
- Louie K.S., Seigneurin A., Cathcart P., Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis // Ann Oncol. 2015. Vol. 26, N 5. P. 848–864. doi: 10.1093/annonc/mdu525
- Ahmed H.U., El-Shater Bosaily A., Brown L.C., et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study // Lancet. 2017. Vol. 389, N 10071. P. 815–822. doi: 10.1016/S0140-6736(16)32401-1
- Alberts A.R., Schoots I.G., Bokhorst L.P., et al. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging? // Eur Urol. 2018. Vol. 73, N 3. P. 343–350. doi: 10.1016/j.eururo.2017.06.019
- Palsdottir T., Nordstrom T., Karlsson A., et al. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study // BMJ Open. 2019. Vol. 9, N 3. P. e027958. doi: 10.1136/bmjopen-2018-027958
- Wynants L., van Smeden M., McLernon D.J., et al. Three myths about risk thresholds for prediction models // BMC Med. 2019. Vol. 17, N 1. P. 192. doi: 10.1186/s12916-019-1425-3
- Sonn G.A., Margolis D.J., Marks L.S. Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy // Urol Oncol. 2014. Vol. 32, N 6. P. 903–911. doi: 10.1016/j.urolonc.2013.08.006
- Sonn G.A., Natarajan S., Margolis D.J., et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device // J Urol. 2013. Vol. 189, N 1. P. 86–91. doi: 10.1016/j.juro.2012.08.095
- Robertson N.L., Hu Y., Ahmed H.U., et al. Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study // Eur Urol. 2014. Vol. 65, N 3. P. 628–634. doi: 10.1016/j.eururo.2012.12.057
- Radtke J.P., Schwab C., Wolf M.B., et al. Multiparametric magnetic resonance imaging (MRI) and MRI — transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen // Eur Urol. 2016. Vol. 70. P. 846–853. doi: 10.1016/j.eururo.2015.12.052
- Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up // Lancet. 2014. Vol. 384, N 9959. P. 2027–2035. doi: 10.1016/S0140-6736(14)60525-0
- Roobol M.J., Steyerberg E.W., Kranse R., et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer // Eur Urol. 2010. Vol. 57, N 1. P. 79–85. doi: 10.1016/j.eururo.2009.08.025
- Meng X., Rosenkrantz A.B., Mendhiratta N., et al. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes // Eur Urol. 2016. Vol. 69, N 3. P. 512–517. doi: 10.1016/j.eururo.2015.06.005
- Vargas H.A., Hötker A.M., Goldman D.A., et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference // Eur Radiol. 2016. Vol. 26, N 6. P. 1606–1612. doi: 10.1007/s00330-015-4015-6
- Radtke J.P., Wiesenfarth M., Kesch C., et al. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies // Eur Urol. 2017. Vol. 72, N 6. P. 888–896. doi: 10.1016/j.eururo.2017.03.039
- van Leeuwen P.J., Hayen A., Thompson J.E., et al. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy // BJU Int. 2017. Vol. 120, N 6. P. 774–781. doi: 10.1111/bju.13814
- Muthigi A., George A.K., Sidana A., et al. Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy // J Urol. 2017. Vol. 197, N 2. P. 327–334. doi: 10.1016/j.juro.2016.08.097
- Cash H., Günzel K., Maxeiner A., et al. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure // BJU Int. 2016. Vol. 118, N 1. P. 35–43. doi: 10.1111/bju.13327
- Bryk D.J., Llukani E., Taneja S.S., et al. The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy // Urology. 2017. Vol. 102. P. 178–182. doi: 10.1016/j.urology.2016.11.017
- Porpiglia F., De Luca S., Passera R., et al. Multiparametric Magnetic Resonance/Ultrasound Fusion Prostate Biopsy: Number and Spatial Distribution of Cores for Better Index Tumor Detection and Characterization // J Urol. 2017. Vol. 198, N 1. P. 58–64. doi: 10.1016/j.juro.2017.01.036
- Fütterer J.J., Briganti A., De Visschere P., et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature // Eur Urol. 2015. Vol. 68, N 6. P. 1045–1053. doi: 10.1016/j.eururo.2015.01.013
- Thompson J.E., Moses D., Shnier R., et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study // J Urol. 2014. Vol. 192, N 1. P. 67–74. doi: 10.1016/j.juro.2014.01.014
- Delongchamps N.B., Portalez D., Bruguière E., et al. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer? // J Urol. 2016. Vol. 196, N 4. P. 1069–1075. doi: 10.1016/j.juro.2016.04.003
- Filson C.P., Natarajan S., Margolis D.J., et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies // Cancer. 2016. Vol. 122, N 6. P. 884–892. doi: 10.1002/cncr.29874
- Rosenkrantz A.B., Verma S., Choyke P., et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR // J Urol. 2016. Vol. 196, N 6. P. 1613–1618. doi: 10.1016/j.juro.2016.06.079
- Simmons L.A.M., Kanthabalan A., Arya M., et al. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy // Br J Cancer. 2017. Vol. 116, N 9. P. 1159–1165. doi: 10.1038/bjc.2017.57
- Hansen N.L., Kesch C., Barrett T., et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy // BJU Int. 2017. Vol. 120, N 5. P. 631–638. doi: 10.1111/bju.13711
- Radtke J.P., Kuru T.H., Bonekamp D., et al. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance // Prostate Cancer Prostatic Dis. 2016. Vol. 19, N 3. P. 283–291. doi: 10.1038/pcan.2016.16
- Henderson D.R., de Souza N.M., Thomas K., et al. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort // Eur Urol. 2016. Vol. 69, N 6. P. 1028–1033. doi: 10.1016/j.eururo.2015.10.010
- Frye T.P., George A.K., Kilchevsky A., et al. Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer // J Urol. 2017. Vol. 197, N 3 Pt 1. P. 640–646. doi: 10.1016/j.juro.2016.08.109
- Recabal P., Assel M., Sjoberg D.D., et al. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance // J Urol. 2016. Vol. 196, N 2. P. 374–381. doi: 10.1016/j.juro.2016.02.084
- Tran G.N., Leapman M.S., Nguyen H.G., et al. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance // Eur Urol. 2017. Vol. 72, N 2. P. 275–281. doi: 10.1016/j.eururo.2016.08.023